Title of article
Efficacy of Rituximab in the Treatment of Plasma Exchange Refractory Thrombotic Thrombocytopenic Purpura
Author/Authors
Sadeghi, Alireza Department of Hematology-Oncology - School of medicine - Isfahan University of Medical Sciences - Isfahan, Iran , Ashrafi, Farzaneh Department of Hematology-Oncology - School of medicine - Isfahan University of Medical Sciences - Isfahan, Iran , Sourani, Arman School of medicine - Isfahan University of Medical Sciences - Isfahan, Iran
Pages
5
From page
87
To page
91
Abstract
Rituximab can induce a durable remission in plasma exchange
refractory thrombotic thrombocytopenic purpura (TTP). Timing of Rituximab
infusion in combination with plasma exchange (PE) and long term follow-up for
probable side effects of such treatment is still lacking.
Methods: This study was conducted among 10 patients with plasma exchange
refractory TTP. According to the study designation, first PE was performed
within 36-48 hours after first dose of rituximab.
Results: Eight of ten (80%) patients received 1 course of rituximab. Two of ten
(20%) patients received another course of rituximab due to relapse. Repsonse
rate (RR) to rituximab in combination with plasma exchange, was 90%. Overall
Survival of the patients was 90% and 1 and 5-year relapse free survival rate (RFS)
was 90% and 83%, respectively. One of the patients expired due to Systemic
Lupus Erythematosus flare up.
Conclusion: According to this study, treatment of refractory TTP with rituximab
in combination with PE could be effective.
Iranian Registry of Clinical Trials: IRCT2017012232125N1
Keywords
Rituximab , Thrombotic thrombocytopenic purpura , Plasma exchange , Refractory
Journal title
Astroparticle Physics
Serial Year
2018
Record number
2481166
Link To Document